Merck expands biotech production capacity in Spain

Germany’s Merck KGaA (MRK: DE) today celebrated a major expansion of its biotech plant in Tres Cantos, Madrid, Spain, resulting in a 50% increase in the facility’s production capacity.

Tres Cantos is the main site of Merck KGaA for the production of the active substances of its fertility treatment Gonal-f and growth hormone disorders treatment Saizen for the whole world. Extension of manufacturing plant will help meet worldwide demand for fertility and growth hormone disorder treatments.

The 15 million-euro ($16.5 million) investment, which was made over the 2014-2016 period, adds 900m2 of biotech production space and a two-floor office building, bringing the total constructed area of the Tres Cantos site to 8,000 m2. The facility complies with the highest international cGMP (current Good Manufacturing Practices) quality standards. It also observes the highest international standards in terms environment, health and safety. It is certified by ISO 14001 environmental management and safety by OHSAS 18001. The site employs 170 highly qualified professionals.

In 2016 alone, Merck has invested around 250 million euros in its healthcare manufacturing network around the world.